Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 2/20 | 0.62 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.62 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | F7 | P08709 | 1/20 | 0.57 |
| ▸ | F3 | P13726 | 1/20 | 0.57 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29479526 | 1.00 | PLOD2 (0.62) | PLOD2PLOD3PLOD1LMNACYP1A2 | |
| SCHEMBL2424897 | 0.85 | LMNA (0.65) | PLOD2PLOD3PLOD1LMNACYP1A2 | |
| SCHEMBL11161284 | 0.81 | ROCK2 (0.66) | LMNACYP3A4ALDH1A1GAAHIF1A | |
| Niacin SCHEMBL4718565 | 0.81 | ALDH1A1 (0.78) | PLOD2PLOD3PLOD1LMNACYP1A2 | |
| SCHEMBL31703901 | 0.80 | LMNA (0.69) | PLOD2PLOD3PLOD1LMNACYP1A2 | |
| SCHEMBL29704465 | 0.80 | LMNA (0.59) | PLOD2PLOD3PLOD1LMNACYP1A2 | |
| SCHEMBL800635 | 0.80 | LMNA (0.69) | PLOD2PLOD3PLOD1LMNACYP1A2 | |
| SCHEMBL27500194 | 0.79 | LMNA (0.62) | PLOD2PLOD3PLOD1LMNACYP1A2 | |
| Niacin SCHEMBL28362910 | 0.78 | ALDH1A1 (0.72) | PLOD2PLOD3PLOD1LMNACYP1A2 | |
| Niacinamide SCHEMBL30011021 | 0.78 | F7 (0.76) | PLOD2PLOD3PLOD1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581071-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2025-07-09 | — | — | EP | claimed |
| WO-2024046712-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-03-07 | — | — | WO | claimed |
| US-20030144541-A1 | Process for preparing alpha-halogenated retones | RHODIA CHIMIE (FR) | 2003-07-31 | — | — | US | claimed |
| EP-1250303-A1 | METHOD FOR PREPARING ALPHA-HALOGENATED KETONES | RHODIA CHIMIE (FR) | 2002-10-23 | — | — | EP | claimed |
| WO-2001055067-A1 | METHOD FOR PREPARING ALPHA-HALOGENATED KETONES | RHODIA CHIMIE (FR) | 2001-08-02 | — | — | WO | claimed |
| WO-2025215286-A1 | SULFONAMIDES, COMPOSITIONS COMPRISING SAID SULFONAMIDES, METHODS FOR THE PREPARATION OF SAID SULFONAMIDES, AND SAID SULFONAMIDES FOR USE AS MEDICAMENT AND IN A METHOD FOR THE TREATMENT OR PREVENTION OF AN OCULAR DISEASE OR CONDITION, OR IDIOPATHIC INTRACRANIAL HYPERTENSION | ITÄ-SUOMEN YLIOPISTO (FI) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025215303-A1 | SULFONAMIDES, COMPOSITIONS COMPRISING SAID SULFONAMIDES, METHODS FOR THE PREPARATION OF SAID SULFONAMIDES, AND SAID SULFONAMIDES FOR USE AS MEDICAMENT AND IN A METHOD FOR THE TREATMENT OR PREVENTION OF AN OCULAR DISEASE OR CONDITION, OR IDIOPATHIC INTRACRANIAL HYPERTENSION | ITÄ-SUOMEN YLIOPISTO (FI) | 2025-10-16 | — | — | WO | disclosed |
| EP-4581071-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024046712-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-03-07 | — | — | WO | disclosed |
| EP-3126545-A2 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | The Trustees of Princeton University (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-3080119-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015153381-A2 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20030144541-A1 | Process for preparing alpha-halogenated retones | RHODIA CHIMIE (FR) | 2003-07-31 | — | — | US | disclosed |
| EP-1250303-A1 | METHOD FOR PREPARING ALPHA-HALOGENATED KETONES | RHODIA CHIMIE (FR) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001055067-A1 | METHOD FOR PREPARING ALPHA-HALOGENATED KETONES | RHODIA CHIMIE (FR) | 2001-08-02 | — | — | WO | disclosed |
| EP-0623103-B1 | PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES | HOECHST SCHERING AGREVO GMBH (DE) | 1997-09-03 | — | — | EP | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5608062-A | Process for preparing trifluoromethyl ketones | HOECHST SCHERING AGREVO GMBH (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0623103-A1 | PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES. | HOECHST SCHERING AGREVO GMBH (DE) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014054-A1 | PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES | HOECHST SCHERING AGREVO GMBH (DE) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144541-A1 | Process for preparing alpha-halogenated retones | ADH1A, ADH1C, RER1 | PLOD2 2756/4885PLOD3 4339/4885PLOD1 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.